Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degraders

Reuters2026/08/06 11:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Monte Rosa highlighted three clinical molecular glue degrader programs with Phase 2 trials starting in 2026 across immunology, inflammation, and oncology.
Novartis-led MRT-6160 (DDY391) showed over 90% VAV1 degradation in Phase 1; a Phase 2a/b Sjögren’s study is active.
MRT-8102 interim Phase 1 data showed about 80-90% NEK7 degradation; Phase 2 starts in H2 2026 for elevated atherosclerotic risk.
MRT-2359 combination data in AR-mutant mCRPC included a 100% PSA response rate; Phase 2 MODeFIRe-1 starts in 3Q 2026.
Cash runway guided into 2029; collaboration payments totaled about $350 million in three years with potential for over $400 million in 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degraders

You may also like

Crypto prices